Biogen sweeps out a Parkinson’s drug on PhII failure as analysts raise alarms about projected revenue slide — despite assuming an aducanumab OK
Biogen’s high-stakes gamble on the Alzheimer’s drug aducanumab just became somewhat more desperate as the big biotech projected a much larger drop in revenue for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
